Catalog product

Optimi Health acquires an extensive catalog of psychedelic products and

VANCOUVER, British Columbia, May 17, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company producing natural, scalable and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has completed the acquisition of a diverse catalog of psilocybin and functional mushroom strains for cultivation at its 20,000 square foot EU-GMP compliant facility in Princeton, British Columbia.

The company’s acquisition includes 24 psychedelic strains and nine functional strains, giving it one of the largest genebanks in the industry. The formulated psychedelic strains will be made available to authorized researchers, Canada’s Special Access Program (SAP), and will be used for on-site research in Optimi’s newly expanded analytical laboratory, while the functional strains will be optimized for the company’s growing whole body, natural supplement brand, Optimi Life.

Last week, Optimi applauded Health Canada’s Notice to Stakeholders that clarified “the importance of drug quality and good manufacturing practices (GMP)” in sourcing psilocybin for clinical trials and SAP. . As the leading cultivator of EU-GMP natural psilocybin, Optimi will begin processing its genetics to provide it to patients requesting a natural product.

In line with its overarching goal of scalable production of safe and EU GMP compliant psilocybin, the Company is undertaking the establishment of an industry-leading mycological genetics base with the goal of determining the comparative efficacy of various strains. of psychedelic mushrooms. Additionally, this acquisition will strengthen Optimi’s position as a premier supplier of natural psilocybin ingredients to approved entities engaged in molecular development and clinical trials.

“We want to be in a place where we can facilitate as wide a range of research as possible,” said Justin Kirkland, Chief Scientific Officer of Optimi Health. “Based on the data available so far, we can say with relative certainty that psychedelic research and any new psilocybin-assisted therapies that may result will not be a one-time process. It is entirely possible that certain strains of mushrooms with varying chemical compositions and potencies lead to varying degrees of efficacy in a wide range of mental health indications when combined with the appropriate therapeutic protocols.

By gathering information from clinical trials, using mushrooms from both its own supply and other sources across the industry, Optimi is committed to working within the necessary regulatory approval processes to ensure access to those who need it.

Optimi CEO Bill Ciprick expanded on the shared scientific and commercial benefits provided by the company’s deep knowledge of psilocybin genetics.

“In conjunction with the recent completion of our analytical laboratory, this acquisition aims to position Optimi as the leading supplier of naturally occurring psilocybin to the burgeoning psychedelic industry,” said Ciprick. “Optimi’s strategic year to market is based on our growing ability to supply and test as many GMP psilocybin strains as needed to ensure the success of the hundreds of clinical trials and drug discovery efforts currently underway. , supporting both the future of psychedelic science and the commercial viability of space as a whole,” Ciprick concluded.


May 27and, the company will host guests and dignitaries from the psychedelic commercial space, the medical and public health fields, local and national politics and the Indigenous community for a grand opening event and facility tour to inaugurate its facilities in Princeton, British Columbia. For those wishing to attend in person or via live stream, please contact event organizer Michael Kydd at [email protected]


Optimi Health is a Canadian homegrown success story producing and supplying EU-GMP grade natural psilocybin and functional mushrooms focusing on the health and wellness markets. Built with the goal of producing scalable natural mushroom formulations for transformational human experiences, the company’s goal is to be the trusted and compassionate premier provider of natural and safe GMP grade psilocybin throughout the world. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities totaling 20,000 square feet in Princeton, in British Columbia.

In order to fully investigate the science of mushrooms, the company has received a research exemption under the Food and Drug Regulations (FDR) from Health Canada for the use of psilocybin and psilocin for scientific purposes through its wholly-owned subsidiary Optimi Labs Inc. Optimi has also obtained a distributor’s license under the Narcotic Control Regulations of Canada governing the possession, distribution, sale, laboratory analysis, and research and development of psilocybin formulations and psilocin. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and regulations to ensure safe and superior Canadian mushroom production.


Investor Relations
Email: [email protected]
Telephone: +1 (902) 880 6121


This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and beliefs about future events. All statements that express or imply discussions of expectations, beliefs, plans, goals, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as ” will likely result”, “are expected”, “expects”, “will continue”, “is planned”, “anticipates”, “believes”, “estimates”, “intends”, “plans”, “plans”, “projection”, “strategy”, “target” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results will differ materially from those expressed in such forward-looking statements. No assurance can be given that such expectations will prove to be correct and undue reliance should not be placed on the forward-looking statements included in this press release. Such statements are not valid. as of the date of this press release. In particular, and without limitation, this press release contains forward-looking statements relating to the activities proposed to be conducted under the Company’s reseller license and related activities relating to plans, direction and objectives. psilocybin and psilocin and Optimi.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially. of those disclosed or implied by such statements. forward-looking statements. These risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under the headings “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form. Company dated January 12, 2022. , and other continuous disclosure documents available under Optimi’s profile at Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors appear from time to time, and it is not possible for Optimi to predict all of them or to assess the impact of each of these factors or the extent to which any one factor, or combination of factors, may cause results significantly different from those contained. in any forward-looking statement.

All forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Photos accompanying this announcement are available at: